ReviewThe lancet. Gastroenterology & hepatology2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles.
Review in The lancet. Gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Progress Towards Eliminating Hepatitis C as a Public Health Threat in Norway.Journal of viral hepatitis · 2026Article
- Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2).Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action.Clinical pharmacology and therapeutics · 2026Article
- A retrospective cohort data-linkage study of secondary healthcare use prior to late blood-borne virus diagnosis in Scotland - A missed opportunity for earlier diagnosis?Epidemiology and infection · 2026Article
- Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study.BMC infectious diseases · 2026Article
- Seroprevalence of hepatitis C virus infection among individuals attending a private clinic in Luanda, Angola.BMC infectious diseases · 2026Article
- From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.The Lancet regional health. Europe · 2026Review
- Mass hepatitis C virus screening among persons in custody in Hong Kong: a modelling cost-effectiveness analysis based on a prospective cohort study.The Lancet regional health. Western Pacific · 2026Article
- Recent Advances in the Epidemiology, Screening, and Management of Hepatitis C Virus Infection in Pregnancy.Gastroenterology & hepatology · 2026Article
- Article
- Feasibility and acceptability of hepatitis C virus self-testing models among high-risk groups in Nasarawa, Nigeria; Exploratory cross-sectional analysis of an implementation study.PLOS global public health · 2026Article
- Efficiency of decentralized screening for hepatitis C in different healthcare settings: retrospective study over 6 years in southeastern Spain.Translational gastroenterology and hepatology · 2026Article
- Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).Open forum infectious diseases · 2025Article
- HCV Testing and Treatment of Adults in the United States: 2014 Through 2021-Data From Two National Commercial Testing Laboratories.Journal of viral hepatitis · 2025Article
- Viral hepatitis: breaking down barriers.Nature reviews. Gastroenterology & hepatology · 2025Article
- Temporal trends in hepatitis C incidence among people tested more than once in Georgia, 2017-23: a nationwide, retrospective cohort.The lancet. Gastroenterology & hepatology · 2025Article
- Revealing New Trends in the Global Burden of Hepatocellular Cancer Related to Hepatitis C Virus by Region, Sociodemographic Index, and Sex.Journal of clinical medicine · 2025Article
- World Hepatitis Day 2025: Progress and Challenges in the Global Elimination of Viral Hepatitis.China CDC weekly · 2025Article
- A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles.The lancet. Gastroenterology & hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development for the elimination of viral hepatitis. To date, profiles from 33 countries and territories have been developed. These profiles reveal that 30 (91%) countries and territories have hepatitis C national action plans, 11 (33%) have systems to monitor hepatitis C-related mortality, 16 (48%) have systems to monitor hepatitis C incidence, and 18 (55%) have systems to track the number of people tested and treated. Some countries and territories continue to uphold barriers to hepatitis C treatment, with 12 (36%) still having partial or full restrictions on prescribing authority for non-specialists. Ten (30%) countries and territories have met the WHO 2025 diagnosis coverage target of 60%, five (15%) have met the treatment target of 50%, and seven (21%) have met the needle and syringe exchange target. Although there are examples of countries and territories across the income spectrum meeting these targets, policy development in low-income and middle-income countries and territories generally lags behind that in high-income countries and territories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.